SMN2 and Duchenne muscular dystrophy: Some SSOs have been already approved by FDA, such as eteplirsen for Duchenne’s muscular dystrophy, which induces the skipping of exon 51 of the DMD gene, and nusinersen for spinal muscle atrophy, which induces the expression of exon 7 of the SMN2 gene63.